問卷

TPIDB > Search Result

Search Result

篩選

List

33Cases

2025-08-01 - 2035-08-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-12-31

Phase III

Active
A phase 3, two-part, randomized, open-label, modified trial comparing BMS-986365 with a trial-administered therapy (including Docetaxel or a second androgen receptor pathway inhibitor [ARPI]) in participants with metastatic castration-resistant prostate cancer (mCRPC) - rechARge
  • Condition/Disease

    Metastatic castration-resistant prostate cancer (mCRPC)

  • Test Drug

    BMS-986365 (CC-94676)

Participate Sites
4Sites

Recruiting4Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-09-28 - 2030-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

2022-02-01 - 2026-03-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-05-20 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-04-15 - 2032-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4